$1.74
3.87% today
Nasdaq, Nov 20, 10:00 pm CET
ISIN
NL0015000AG6
Symbol
LVTX

LAVA Therapeutics NV Stock price

$1.81
+0.32 21.48% 1M
+0.55 43.65% 6M
+0.86 90.33% YTD
+0.26 16.40% 1Y
-3.55 66.23% 3Y
-13.19 87.93% 5Y
-13.19 87.93% 10Y
-13.19 87.93% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.03 1.69%
ISIN
NL0015000AG6
Symbol
LVTX
Industry

Key metrics

Basic
Market capitalization
$47.6m
Enterprise Value
$-8.6m
Net debt
positive
Cash
$56.2m
Shares outstanding
26.3m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.5
P/B
2.4
Financial Health
Equity Ratio
34.6%
Return on Equity
-89.7%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-33.3m
EBIT
- | $-27.8m
Net Income
- | $-22.5m
Free Cash Flow
$-15.9m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
- | -13.8%
EBIT
- | 6.5%
Net Income
- | 10.2%
Free Cash Flow
41.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.6
Short interest
2.7%
Employees
34
Rev per Employee
$350.0k
Show more

Is LAVA Therapeutics NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

LAVA Therapeutics NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a LAVA Therapeutics NV forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a LAVA Therapeutics NV forecast:

Hold
57%
Sell
43%

Financial data from LAVA Therapeutics NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
91% 91%
188%
- Research and Development Expense 47 47
59% 59%
396%
-58 -58
91% 91%
-485%
- Depreciation and Amortization -0.14 -0.14
111% 111%
-1%
EBIT (Operating Income) EBIT -58 -58
83% 83%
-484%
Net Profit -49 -49
72% 72%
-411%

In millions USD.

Don't miss a Thing! We will send you all news about LAVA Therapeutics NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

LAVA Therapeutics NV Stock News

Neutral
GlobeNewsWire
7 days ago
UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA's common shares, representing approximately 87% of LAVA's outstanding common shares, were validly tendered and not withdrawn prior to the expiration of the initial offering period one minute after 11:59 p.m.
Neutral
GlobeNewsWire
10 days ago
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation (“XOMA”) (NASDAQ: XOMA).
Neutral
PRNewsWire
about one month ago
MILWAUKEE , Oct. 20, 2025 /PRNewswire/ --The Ademi Firm is investigating Lava (Nasdaq: LVTX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
More LAVA Therapeutics NV News

Company Profile

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Head office Netherlands
CEO Stephen Hurly
Employees 34
Founded 2016
Website www.lavatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today